Versant Vantage I, L.P.
CIK 0001765253
10% Owner
Filings
10
Latest Sep 23, 2025
Issuers covered
6
Showing
10 of 10
Page 1
Track record
8 of 21 open-market trades scored (38% price coverage) - 13 issuers without price data. Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).
| Horizon | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|
| 30 days | 8 | 75% | +11.2% | +16.7% | +33.5% | -10.6% |
| 90 days | 8 | 50% | +6.8% | +19.1% | +61.2% | -51.8% |
| 180 days | 8 | 63% | +24.5% | +25.1% | +65.9% | -9.2% |
| 365 days | 8 | 38% | -2.1% | -7.4% | +55.2% | -33.4% |
Issuers
Companies where Versant Vantage I, L.P. has filed
| Ticker | Issuer | Filings | Last filed |
|---|---|---|---|
| GLUE | Monte Rosa Therapeutics, Inc. | 3 | Oct 30, 2024 |
| LVTX | Lava Therapeutics NV | 2 | Sep 23, 2025 |
| OYST | Oyster Point Pharma, Inc. | 2 | Jan 4, 2023 |
| BDTX | Black Diamond Therapeutics, Inc. | 1 | Aug 30, 2024 |
| CTNM | Contineum Therapeutics, Inc. | 1 | Apr 11, 2024 |
| RPTX | Repare Therapeutics Inc. | 1 | Jun 7, 2022 |
All filings
10 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|